Cytokinetics Seeks ALS Success By Focusing On Lung Function
Executive Summary
Despite an earlier Phase II failure on broader ALS endpoint, biotech thinks it can demonstrate efficacy in slowing lung-function decline in ALS patients.
You may also be interested in...
Cytokinetics’ Failure In ALS Clears Way For Focus On Aficamten
With a data monitoring committee finding no signs of efficacy in a Phase III trial of ALS candidate reldesemtiv, Cytokinetics can conserve cash and center on aficamten for hypertrophic cardiomyopathy.
With Phase III Failure, Cytokinetics Shelves Tirasemtiv, Pivots To ALS Backup
Partnered with Astellas, the San Francisco-area biotech hopes next-generation CK-107 will succeed in a measure of slow vital capacity due to stronger potency and better tolerability compared to tirasemtiv.
Seven Clinical Trial Read-Outs Due In Q4
The last three months of the year should see data reporting from a number of key studies for novel products including Roche's emicizumab. Scrip takes a look at some of the more interesting studies expected by year end, with the help of analysts from Informa's Biomedtracker.